Connor Healey, MD
Cardiovascular Disease · Albany, NYNPI 1316206998
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 333 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Novartis at 28.3% of the total.
Across 333 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Pfizer$494
- E.r. Squibb & Sons, L.L.C.$354
- AstraZeneca$313
- Amgen$257
- Boehringer Ingelheim$242
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,953100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 145 | $1,400 |
| Pfizer | 29 | $494 |
| E.r. Squibb & Sons, L.L.C. | 20 | $354 |
| AstraZeneca | 17 | $313 |
| Amgen | 15 | $257 |
| Boehringer Ingelheim | 11 | $242 |
| Johnson & Johnson | 11 | $228 |
| Kiniksa Pharmaceuticals, Ltd. | 13 | $221 |
| Merck | 11 | $190 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $145 |
| Abbott | 6 | $141 |
| Cvrx, Inc. | 6 | $129 |
| Abiomed | 2 | $98 |
| Alnylam Pharmaceuticals Inc. | 4 | $94 |
| Lexicon Pharmaceuticals, Inc. | 4 | $72 |
| Scpharmaceuticals Inc. | 4 | $70 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $65 |
| Chiesi USA, Inc. | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Astellas Pharma US Inc | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Portola Pharmaceuticals, LLC | 2 | $24 |
| Gilead | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Bayer | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
How this compares
$4,953 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 649 | $913,143 |
| Repatha SureclickEvolocumab | 194 | $240,208 |
| EntrestoSacubitril/Valsartan | 66 | $106,984 |
| JardianceEmpagliflozin | 59 | $65,985 |
| MounjaroTirzepatide | 50 | $57,321 |
| XareltoRivaroxaban | 35 | $48,614 |
| MultaqDronedarone Hcl | 26 | $46,995 |
| WegovySemaglutide | 23 | $37,552 |
| OzempicSemaglutide | 26 | $31,218 |
| Praluent PenAlirocumab | 33 | $23,926 |
| Rosuvastatin Calcium | 814 | $14,575 |
| Atorvastatin Calcium | 967 | $11,516 |
| Metoprolol Succinate | 826 | $11,244 |
| Droxidopa | 29 | $8,736 |
| Bumetanide | 264 | $7,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $494 | $913,143649 claims |
| NovartisEntresto | $1,400 | $106,98466 claims |
| Boehringer IngelheimJardiance | $242 | $65,98559 claims |
| Johnson & JohnsonXarelto | $228 | $48,61435 claims |
| Sanofi-aventis U.S. LLCMultaq | $57 | $46,99526 claims |
| MerckVerquvo | $190 | $7,06911 claims |
| AstraZenecaCrestor | $313 | $2,06612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Albany
- Augustin DelagoAlbany$1.8M
- Rizwan AlimohammadAlbany$349K
- Edward PhilbinAlbany$226K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.